Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

Completed · Not applicable

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.

Key facts

Study ID

NCT00018642

Run by

US Department of Veterans Affairs

Starts

1997-04-01

Expected to finish

2002-03-01

Last updated by the study team

2009-01-21

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
• Between the ages 18-60.
• A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms.

You may not qualify if…

• Organic brain disease.
• Mental Retardation
• Chronic medical illness which would make antipsychotic medication inappropriate.

Where it is running

• VA Greater Los Angeles Healthcare System — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.